Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer [0.03%]
肿瘤内的免疫异质性决定了肺癌PD-(L)1阻断的疗效差异
Laura Cipriani,Davide Mascolo,Stefano Scalera et al.
Laura Cipriani et al.
Purpose: Clinical outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) range from durable disease control to rapid progression. Current biomarkers have limited ability to predict these d...
Sex Steroid Hormone Regulation of T cell Function and Anti-Tumor Immunity [0.03%]
性类固醇激素对T细胞功能和抗肿瘤免疫的调节作用
Amanda Heard,Rachel T Huynh,Christy R Hagan et al.
Amanda Heard et al.
Cancer immunotherapy treatment has revolutionized cancer care. Of the many FDA approved immunotherapies, immune checkpoint inhibitors are the most widely prescribed, given their utility in treating both solid and hematopoietic diseases and ...
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib [0.03%]
EGFR突变的晚期肺腺癌患者一线使用奥希替尼治疗时出现EGFR扩增的临床意义分析
Alessandro Di Federico,Federica Pecci,Mark Jeng et al.
Alessandro Di Federico et al.
Purpose: With rapidly expanding treatment options for patients with EGFR-mutated non-small cell lung cancer (NSCLC), identifying biomarkers that may assist treatment selection is critical. The impact of EGFR amplification...
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus [0.03%]
仑伐西姆单抗和托贝西姆单抗与尼伏鲁玛对比治疗晚期或转移性食管鳞细胞癌的II期生物标志物研究：一项随机试验
Lucjan Wyrwicz,Arunee Dechaphunkul,Jong-Seok Lee et al.
Lucjan Wyrwicz et al.
Purpose: The bispecific antibodies lomvastomig and tobemstomig block the immune checkpoint receptor PD-1 and either TIM-3 or LAG-3, respectively. This phase 2 study assessed their efficacy compared with nivolumab in CPI-n...
The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma [0.03%]
铁基因H63D多态性促进胰腺导管腺癌的侵袭性疾病表型
Federica Rubbino,Luana Greco,Alessandro Scagliotti et al.
Federica Rubbino et al.
Purpose: Controversy exists regarding the association between HFE H63D polymorphism and pancreatic ductal adenocarcinoma (PDAC). This study initially assessed the frequency of H63D in PDAC patients and subsequently invest...
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy [0.03%]
一类临床DNA聚合酶θ聚合酶结构域抑制剂ART6043的药理学特征及其增强PARP抑制剂疗效的作用机制研究
Helen M R Robinson,Vera Grinkevich,Jayesh B Majithiya et al.
Helen M R Robinson et al.
DNA polymerase theta (Polθ ) is the central component of the DNA double strand break repair process of microhomology mediated end-joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumour-selective expression, ...
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer [0.03%]
ctDNA肿瘤突变分数在晚期非小细胞肺癌免疫治疗选择中的作用
Filippo G Dall&#x;Olio,Wael Zrafi,Damien Vasseur et al.
Filippo G Dall&#x;Olio et al.
Background: Immune checkpoint blockers (ICBs) have transformed advanced non-small cell lung cancer (aNSCLC) treatment, but identifying patients who benefit from adding chemotherapy remains challenging, especially in PD-L1...
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial [0.03%]
阿贝西利联合福尔司特与艾伏美替尼治疗HR+/HER2-且既往接受过CDK4/6抑制剂的晚期乳腺癌患者：单臂I期临床试验
Adrienne G Waks,Elia Segui,Tianyu Li et al.
Adrienne G Waks et al.
Purpose: The efficacy of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative metastatic breast cancer is limited by resistance mechanisms, including mitogen-activated protein ki...
Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial [0.03%]
可切除非小细胞肺癌的新辅助化疗免疫治疗的肿瘤免疫微环境差异及反应：单组II期临床试验
Minjiang Chen,Rongzhen Li,Zuolin Cheng et al.
Minjiang Chen et al.
Background: Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer (NSCLC), yet the spatial immune features associated with treatment response remain unclear. ...
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors [0.03%]
一种转化研究平台在多种FGFR改变的实体瘤中揭示FGFR抑制剂疗效信号和耐药机制中的应用
Cinta Hierro,Mònica Sánchez-Guixé,Gabi Tarcic et al.
Cinta Hierro et al.
Purpose: The predictive value of FGFR amplifications (amp) and the role of FGFR mutations (mut) beyond known activating variants remain unclear. We aimed to establish a translational research platform to characterize FGFR...